Kynos Therapeutics Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Employees
-
9
- Latest Deal Type
-
M&A
Kynos Therapeutics General Information
Description
Operator of a Biotech company intended to fulfill the unmet medical need for new therapies. The company's therapy offers to block the action of Kaiser-Meyer-Olkin (KMO) which is a key enzyme at the interface of inflammation, immunity, and metabolism and regulation of systemic inflammation and the pathology of conditions where there is a pressing need for new medicines, providing the clinical industry with a new generation of potent inhibitors.
Contact Information
Website
www.kynostx.comCorporate Office
- 1-3 Charter Square
- Sheffield S1 4HS
- England, United Kingdom
Corporate Office
- 1-3 Charter Square
- Sheffield S1 4HS
- England, United Kingdom
Kynos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 29-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 07-Apr-2022 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 01-Mar-2022 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Jan-2022 | Completed | Pre-Clinical Trials | |||
| 1. University Spin-Out | Completed | Startup |
Kynos Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A |
Kynos Therapeutics Patents
Kynos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10246447-B2 | 3-(6-chloro-3-oxo-3,4-dihydro-(2h)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as kmo inhibitors | Active | 22-May-2015 | ||
| US-20180170920-A1 | 3-(6-chloro-3-oxo-3,4-dihydro-(2h)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as kmo inhibitors | Active | 22-May-2015 | ||
| US-10611756-B2 | Method of treating pancreatitis using 1,4-benzoxazine derivatives | Active | 22-May-2015 | ||
| US-20190169178-A1 | Methods | Active | 22-May-2015 | ||
| US-10273232-B2 | 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors | Active | 19-Dec-2014 | A61K31/423 |
Kynos Therapeutics Signals
Kynos Therapeutics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Creative Destruction Lab | Accelerator/Incubator | |||
| Epidarex Capital | Venture Capital | Minority | ||
| Gershon Capital | Venture Capital | Minority | ||
| IP Group | Venture Capital | Minority | ||
| Innovate UK | Government |
Kynos Therapeutics FAQs
-
When was Kynos Therapeutics founded?
Kynos Therapeutics was founded in 2020.
-
Where is Kynos Therapeutics headquartered?
Kynos Therapeutics is headquartered in Sheffield, United Kingdom.
-
What is the size of Kynos Therapeutics?
Kynos Therapeutics has 9 total employees.
-
What industry is Kynos Therapeutics in?
Kynos Therapeutics’s primary industry is Drug Discovery.
-
Is Kynos Therapeutics a private or public company?
Kynos Therapeutics is a Private company.
-
What is Kynos Therapeutics’s current revenue?
The current revenue for Kynos Therapeutics is .
-
How much funding has Kynos Therapeutics raised over time?
Kynos Therapeutics has raised $8.53M.
-
Who are Kynos Therapeutics’s investors?
Creative Destruction Lab, Epidarex Capital, Gershon Capital, IP Group, and Innovate UK are 5 of 8 investors who have invested in Kynos Therapeutics.
-
When was Kynos Therapeutics acquired?
Kynos Therapeutics was acquired on 29-Oct-2024.
-
Who acquired Kynos Therapeutics?
Kynos Therapeutics was acquired by Dr Falk Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process